To delineate the precise molecular intervention details of NCTD in lung cancer, this study examined the selectivity of NCTD in targeting UBE2C to inhibit NSCLC progression and revealed that NCTD decreased UBE2C in dose dependent(4−20 μg/ml) and time-dependent (24−60 h) manners in A549 cells (Fig. 6a, b; Supplementary Figure S2A and C), in which concentration-dependent repression of UBE2C induced by NCTD arrested A549 cell growth and NCTD blocked UBE2C overexpression-induced cellular proliferation (Fig. 6c; Supplementary Figure S2B−E). The gene discussed is UBE2C; the disease is lung cancer.